Siemens Healthineers

InkSpace Imaging makes their advanced MRI coils available to Siemens Healthineers Magnetom Scanners

Retrieved on: 
Friday, March 8, 2024

PLEASANTON, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- InkSpace Imaging proudly announces a major leap forward in advancing diagnostic imaging capabilities.

Key Points: 
  • PLEASANTON, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- InkSpace Imaging proudly announces a major leap forward in advancing diagnostic imaging capabilities.
  • Today, the company revealed the successful certification of its groundbreaking Snuggle ™ and Silhouette™ MRI body arrays for compatibility with all Siemens Healthineers TIM 4G 3T Magnetom MRI scanners in the United States.
  • The blanket-like MRI coils offer an unparalleled patient experience, designed to alleviate anxiety, reduce the need for sedation, and minimize additional procedures.
  • We are thrilled that our patient-focused MRI coils are now accessible to all Siemens Healthineers 3T MRI scanner sites in the US."

Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 7, 2024

TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2023.
  • Fourth quarter 2023 revenue increased 60% from approximately $1.3 million in the same three-month period a year ago.
  • G&A expenses for the 2023 fourth quarter increased by 41% to approximately $3.0 million, compared with approximately $2.1 million in the same period in 2022.
  • Fourth quarter 2023 S&D expenses increased by 74% to approximately $2.9 million, compared with $1.7 million in the fourth quarter of 2022.

Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure

Retrieved on: 
Tuesday, February 27, 2024

TULSA is a “one-and-done” procedure, performed in a single session that takes a few hours, and no hospital stay is required.

Key Points: 
  • TULSA is a “one-and-done” procedure, performed in a single session that takes a few hours, and no hospital stay is required.
  • At less than 7,700 Lbs and 80 inches high, MAGNETOM Free.Max is the most lightweight, compact whole-body scanner ever offered by Siemens Healthineers.
  • I commend the teams at Siemens Healthineers and Profound as they work to achieve the convergence of their respective diagnostic and interventional MR technologies.
  • We look forward to collaborating with Profound to help expand access to TULSA as well.

Industry Leaders Announce the Cardiac PET Industry Coalition (CPIC)

Retrieved on: 
Tuesday, March 5, 2024

WILMINGTON, Del., March 5, 2024 /PRNewswire-PRWeb/ -- Leading manufacturers in cardiac positron emission tomography (PET) imaging launched the Cardiac PET Industry Coalition (CPIC), an initiative dedicated to promoting federal policies that advance health outcomes for patients with cardiovascular disease and the availability of cardiac PET diagnostics. CPIC will champion fair and transparent coverage and reimbursement policies that facilitate access to cardiac PET, align practitioners with regard to research opportunities, highlight the clinical and economic benefit of this modality, and provide expanded opportunities to educate healthcare providers and policymakers on the overall value of cardiac PET.

Key Points: 
  • WILMINGTON, Del., March 5, 2024 /PRNewswire-PRWeb/ -- Leading manufacturers in cardiac positron emission tomography (PET) imaging launched the Cardiac PET Industry Coalition (CPIC) , an initiative dedicated to promoting federal policies that advance health outcomes for patients with cardiovascular disease and the availability of cardiac PET diagnostics.
  • "The clinical benefits of cardiac PET imaging are well-documented for making patient care and treatment decisions.
  • "I'm proud of the work the Coalition is doing to increase awareness, maintain appropriate reimbursement and expand the adoption of cardiac PET imaging."
  • Phil Cranmer, Cardiac PET Industry Coalition (CPIC), 1 (215) 888-0040, [email protected] , https://cpicoalition.com/
    View original content to download multimedia: https://www.prweb.com/releases/industry-leaders-announce-the-cardiac-pet...

SmartAlpha Partners with Siemens Healthineers to advance AI-powered Workflow Efficiencies in Ultrasound

Retrieved on: 
Friday, March 1, 2024

VIENNA, March 1, 2024 /PRNewswire/ -- SmartAlpha has announced a partnership with Siemens Healthineers with a signing ceremony at the European Congress of Radiology (ECR).

Key Points: 
  • VIENNA, March 1, 2024 /PRNewswire/ -- SmartAlpha has announced a partnership with Siemens Healthineers with a signing ceremony at the European Congress of Radiology (ECR).
  • SmartAlpha's technology has made significant advances through the development of AI-guidance features for real-time ultrasound scanning.
  • "This collaboration represents a significant milestone in the journey of our AI solutions in ultrasound," stated Utku Kaya, Co-founder and CEO of SmartAlpha.
  • "While ultrasound manufacturers are working to enhance their devices, our commitment lies in making them smarter in an unparalleled manner to improve the efficiency and workflow of ultrasound imaging."

Varian Receives FDA 510(k) Clearance for TrueBeam and Edge Radiotherapy Systems Featuring HyperSight Imaging Solution

Retrieved on: 
Thursday, February 29, 2024

HyperSight is designed to enhance accuracy in delivering radiotherapy treatments, with the goal of effective protection of healthy tissues

Key Points: 
  • HyperSight is designed to enhance accuracy in delivering radiotherapy treatments, with the goal of effective protection of healthy tissues
    PALO ALTO, Calif., Feb. 29, 2024 /PRNewswire/ -- Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for TrueBeam and Edge radiotherapy systems featuring HyperSight imaging solution.
  • By extending the groundbreaking HyperSight imaging solution optional feature to the TrueBeam and Edge systems, Varian continues to revolutionize imaging inside the radiotherapy treatment room and adds new capabilities and workflows across the entire suite of linear accelerators.
  • HyperSight on TrueBeam and Edge acquires images for all anatomical sites with a 50% faster gantry rotation, significantly reducing acquisition time.
  • VARIAN, TRUEBEAM, EDGE, ETHOS, HALCYON, HYPERSIGHT are trademarks of Varian Medical Systems, Inc., pending or registered U.S. Pat.

Dave Hickey Announces Intent to Retire from BD

Retrieved on: 
Tuesday, February 27, 2024

FRANKLIN LAKES, N.J., Feb. 27, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Dave Hickey has informed the company of his intent to retire from BD, effective July 1.

Key Points: 
  • FRANKLIN LAKES, N.J., Feb. 27, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Dave Hickey has informed the company of his intent to retire from BD, effective July 1.
  • Hickey is currently executive vice president and president of the Life Sciences segment for BD, a position he has held since January 2021.
  • Prior to his current role, Hickey was president of Integrated Diagnostic Solutions from 2019 to 2021, and president of Diagnostic Systems prior to that.
  • Before joining BD in 2014, Hickey served in a range of executive leadership positions at Siemens Healthcare.

Internet of Medical Things (IoMT) Market to reach over US$ 385.01 Bn by the year 2031 - Explained Details | Exclusive Study by InsightAce Analytic

Retrieved on: 
Wednesday, February 21, 2024

This strategic agreement strengthens Medtronic's leadership in AI-integrated healthcare products and marks a significant step in implementing AI into endoscopic treatment.

Key Points: 
  • This strategic agreement strengthens Medtronic's leadership in AI-integrated healthcare products and marks a significant step in implementing AI into endoscopic treatment.
  • In October 2023, SAP SE reported that Siemens Healthineers AG's digital transformation journey will be enabled by the RISE with SAP solution.
  • @ https://www.insightaceanalytic.com/enquiry-before-buying/1559
    Internet of Medical Things (IoMT) Market Dynamics:
    Despite the evident potential of the Internet of Medical Things (IoMT), the market faces significant restrictions primarily stemming from heightened Data Security and Privacy Concerns.
  • Despite the evident potential of the Internet of Medical Things (IoMT), the market faces significant restrictions primarily stemming from heightened Data Security and Privacy Concerns.

Internet of Medical Things (IoMT) Market to reach over US$ 385.01 Bn by the year 2031 - Explained Details | Exclusive Study by InsightAce Analytic

Retrieved on: 
Wednesday, February 21, 2024

This strategic agreement strengthens Medtronic's leadership in AI-integrated healthcare products and marks a significant step in implementing AI into endoscopic treatment.

Key Points: 
  • This strategic agreement strengthens Medtronic's leadership in AI-integrated healthcare products and marks a significant step in implementing AI into endoscopic treatment.
  • In October 2023, SAP SE reported that Siemens Healthineers AG's digital transformation journey will be enabled by the RISE with SAP solution.
  • @ https://www.insightaceanalytic.com/enquiry-before-buying/1559
    Internet of Medical Things (IoMT) Market Dynamics:
    Despite the evident potential of the Internet of Medical Things (IoMT), the market faces significant restrictions primarily stemming from heightened Data Security and Privacy Concerns.
  • Despite the evident potential of the Internet of Medical Things (IoMT), the market faces significant restrictions primarily stemming from heightened Data Security and Privacy Concerns.

Enigma Biomedical - USA Announces Appointment of Hartmuth Kolb, PhD as Chief Scientific Officer

Retrieved on: 
Tuesday, February 13, 2024

Enigma Biomedical USA (EB) today announced the appointment of Hartmuth Kolb, PhD as Chief Science Officer (CSO).

Key Points: 
  • Enigma Biomedical USA (EB) today announced the appointment of Hartmuth Kolb, PhD as Chief Science Officer (CSO).
  • Dr. Kolb’s passion for innovation and scientific rigor has driven his extensive career and broad recognition.
  • He will join Enigma at the beginning of March, 2024.
  • In his 10 year tenure at Johnson & Johnson Innovative Medicine, he served as the Vice President, Neuroscience Biomarkers and Global Head of Imaging.